The consistent high expression of EZH2 across different MB subgroups [30, 31, 44], and no expression of EZH2 after week 34 GSA, provides a possibility for targeted therapy with EZH2 inhibitors in medulloblastoma [31, 45, 46]. This evidence concerns the gene EZH2 and medulloblastoma.